BN Business News
Unternehmen hinzufügen →
Diese Übersetzung wird noch vorbereitet. Bis dahin zeigen wir vorübergehend die englische Originalversion.

Geschäft · 24.11.20001 Min. Lesezeit

Digoxin Products for Oral Use; Reaffirmation of New Drug Status and Conditions for Marketing

Lokale automatische Übersetzung · Originalsprache der Quelle

Zusammenfassung

The Food and Drug Administration (FDA) is reaffirming its determination that digoxin products for oral use (tablets and elixir) are new drugs and announcing the conditions for marketing the products. Manufacturers who wish to begin to market or to continue marketing digoxin products for oral use must submit new drug applications (NDA's) or abbreviated new drug applications (ANDA's). Elsewhere in this issue of the Federal Register, FDA is publishing a proposed rule to revoke the regulations that establishes conditions for marketing digoxin products for oral use.

Originalsprache der Quelle: Federal Register — Food and Drug AdministrationOriginalquelle öffnen →

Weitere Themen

Business-Analysen →